About the KONFIDENT StudyAbout the KOMPLETE StudyAbout the Effectus Patient Identification ProgramSign Up Here
Do you see adolescent and adult patients with hereditary angioedema (HAE) type I or type II?
Learn how you can get involved to support a nearby study that is enrolling qualified patients.
About the KONFIDENT Research Study
KalVista Pharmaceuticals is currently conducting the KONFIDENT Study. The purpose of the KONFIDENT Study is to understand the effects of an investigational oral medication, KVD900, in patients 12 years of age and older with HAE type I or type II. The study is evaluating 2 different doses to see which one may be best as a safe on-demand treatment for HAE attacks.
KVD900 is an investigational oral medication designed for on-demand treatment for HAE attacks. It works by inhibiting the activation of plasma kallikrein, which reduces swelling and may help in the treatment of HAE.
For more information about the study and investigational drug, please visit: https://konfidentstudy.com
How You Can Get Involved
As a physician who sees patients with HAE, you are invited to participate in the Effectus Patient Identification and Consultation Program to help identify candidates for the KONFIDENT Study. You will be asked to consult with patients in a neutral manner about the study and assess their interest in participating at a nearby study site. Patients may be able to take part if they meet high-level criteria (key study criteria will be provided to you upon onboarding). At the study site, patients will undergo formal study screening to determine eligibility.
Compensation at fair market value will be available for physicians who participate and meet program requirements.
The Effectus Patient Identification and Consultation Program
Do you see adult patients with hereditary angioedema (HAE) type I or type II?
Learn how you can get involved to support a nearby study that is enrolling qualified patients.
About the KOMPLETE Research Study
KalVista Pharmaceuticals is currently conducting the KOMPLETE Study. The purpose of the KOMPLETE Study is to understand the effects of an investigational oral medication, KVD824, in adults 18 years of age and older with HAE type I or type II. The study is evaluating 3 different doses to see which one may be best as a safe prophylaxis treatment for HAE attacks.
KVD824 is an investigational oral medication designed to prevent HAE attacks. It works by inhibiting the activation of plasma kallikrein, which reduces swelling and may help in the treatment of HAE.
For more information about the study and investigational drug, please visit: https://kompletestudy.com
How You Can Get Involved
As a physician who sees patients with HAE, you are invited to participate in the Effectus Patient Identification and Consultation Program to help identify candidates for the KOMPLETE Study. You will be asked to consult with patients in a neutral manner about the study and assess their interest in participating at a nearby study site. Patients may be able to take part if they meet high-level criteria (key study criteria will be provided to you upon onboarding). At the study site, patients will undergo formal study screening to determine eligibility.
Compensation at fair market value will be available for physicians who participate and meet program requirements.
The Effectus Patient Identification and Consultation Program
Effectus Patient Identification and Consultation Program Overview
Support Provided
Effectus will be your trusted partner throughout your participation, helping to facilitate your patients to the study site and thus relieving the burden on your practice. If you wish to participate, you will be asked to review and sign a Services Agreement with Effectus, which outlines your program responsibilities and compensation. Participation is completely voluntary, and you can opt out at any time. Background on the studies, program materials, and program logistics will be reviewed in detail during a 1-hour virtual training session.
Why Participate?
The program provides an opportunity to contribute to the research and advancement of a potential new prophylaxis and on-demand treatment for HAE attacks. The study also allows physicians the opportunity to offer alternative potential treatment options to their patients.
Sign a services
agreement.
Receive a package of
program materials and
complete a simple, one-hour
virtual training session.
Utilize key screening
criteria to identify
potentially eligible
patients.
If the patient meets the criteria,
conduct a neutral consultation
about the availability of the
nearby study and gauge the
patient’s interest.
If the patient is interested in
participation, our team of dedicated
Patient Facilitators help ensure a
smooth patient transfer from your
office to the study.
The patient is scheduled
and presents at the study
site for the screening
appointment.
The patient’s enrollment
status is determined and is
relayed back to the treating
HCP by Effectus.
For more information on our program, please visit https://www.effectusctr.com/physician-network/.
The Effectus Patient Identification and Consultation Program
Contact Us
Montana Markell, Project Coordinator
Phone: 973-753-2430
Email: mmarkell@effectusctr.com